Voclosporin

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 192 publications

Advances in the treatment of systemic lupus erythematosus: Biologicals, small-molecular agents, and cell-depleting therapies coming to the clinic.

Advances in the treatment of systemic lupus erythematosus: Biologicals, small-molecular agents, and cell-depleting therapies coming to the clinic.

Journal: Journal of internal medicine

Published: August 05, 2026

Lupus nephritis treatment: a comprehensive overview of recent meta-analyses and future directions.

Lupus nephritis treatment: a comprehensive overview of recent meta-analyses and future directions.

Journal: Immunotherapy

Published: July 18, 2026

Voclosporin Preserves Mitochondrial Function Compared With Cyclosporine A in Perfused Human Proximal Tubule Microphysiological Systems.

Voclosporin Preserves Mitochondrial Function Compared With Cyclosporine A in Perfused Human Proximal Tubule Microphysiological Systems.

Journal: bioRxiv : the preprint server for biology

Published: July 17, 2026

Navigating the therapeutic landscape: Biologics and immunosuppressive therapy in lupus nephritis during pregnancy.

Navigating the therapeutic landscape: Biologics and immunosuppressive therapy in lupus nephritis during pregnancy.

Journal: Lupus

Published: July 09, 2026

Management of systemic lupus erythematosus with kidney involvement: systematic literature review to inform the 2025 update of EULAR recommendations.

Management of systemic lupus erythematosus with kidney involvement: systematic literature review to inform the 2025 update of EULAR recommendations.

Journal: EULAR rheumatology open

Published: June 29, 2026

Evaluation of Puromycin-Induced Podocyte Injury and Protective Effects of Voclosporin Using Induced Pluripotent Stem Cells from a Patient with Nephrotic Syndrome Harboring an INF2 Variant.

Evaluation of Puromycin-Induced Podocyte Injury and Protective Effects of Voclosporin Using Induced Pluripotent Stem Cells from a Patient with Nephrotic Syndrome Harboring an INF2 Variant.

Journal: Stem cells and development

Published: June 18, 2026

Childhood-Onset Lupus Nephritis in the Era of Triple Therapy and Steroid Minimization.

Childhood-Onset Lupus Nephritis in the Era of Triple Therapy and Steroid Minimization.

Journal: Children (Basel, Switzerland)

Published: June 13, 2026

Drug-Drug Interactions Between Oral Anticoagulants and Calcineurin Inhibitors in Nephrotic Syndrome for Management of Thromboembolism.

Drug-Drug Interactions Between Oral Anticoagulants and Calcineurin Inhibitors in Nephrotic Syndrome for Management of Thromboembolism.

Journal: Biomedicines

Published: June 02, 2026

Comparative Analysis of Lupus Nephritis Guidelines: ACR 2025, EULAR 2025, and Kdigo 2024.

Comparative Analysis of Lupus Nephritis Guidelines: ACR 2025, EULAR 2025, and Kdigo 2024.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: May 08, 2026

The Inverted Pyramid Approach: Early Combination Therapy With Voclosporin and Obinutuzumab in Active Lupus Nephritis.

The Inverted Pyramid Approach: Early Combination Therapy With Voclosporin and Obinutuzumab in Active Lupus Nephritis.

Journal: Cureus

Published: April 22, 2026

Methodological considerations on the safety and efficacy of adding voclosporin to standard treatment for lupus nephritis: a commentary.

Methodological considerations on the safety and efficacy of adding voclosporin to standard treatment for lupus nephritis: a commentary.

Journal: International urology and nephrology

Published: April 08, 2026

The role of monoclonal antibodies in the treatment of lupus nephritis.

The role of monoclonal antibodies in the treatment of lupus nephritis.

Journal: Expert opinion on biological therapy

Published: April 07, 2026

Showing 1-12 of 192

Last Updated: 09/26/2026